TNFSF11 and bone metastasis: Currently, there is a lack of systemic treatment measures for bone metastasis, but bisphosphonates or RANKL inhibitors can be given to reduce the destruction of osteoclasts, promote the secretion of osteoblast factors, and reduce the risk of osteolytic damage (21–23).